CRIP1 is upregulated in exhausted CD8+ T-cells, and the development of inhibitors against CRIP1 may relieve immunosuppression, improve exhausted CD8+ T-cells, and enhance anti-tumor ability. The gene discussed is CD8A; the disease is neoplasm.